After five years of Dupixent’s reign for Sanofi, the U.K.'s medicines regulatory agency is warning about the risks of ocular side effects. In a Tuesday update from the U.K.'s Medicines and Healthcare ...

Aslan Pharmaceuticals is trying to come for Dupixent’s billion-dollar crown in atopic dermatitis, but with mid-stage data showing a more comparable than superior profile, the company hopes less ...

QUESTION: In a recent column about the challenges of treating eczema (atopic dermatitis), you described a number of over-the-counter treatments as well as modern prescription medicines. In particular, ...

I started taking a second biologic to treat my eczema and asthma at the end of last year. My allergist and dermatologist had recommended I begin Dupixent (dupilumab) injections about five years ago, ...

Bullous pemphigoid (BP) is an autoimmune disorder that mainly affects older adults. The condition causes your immune system to attack proteins that hold the layers of your skin together. This damages ...

BP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesions TARRYTOWN, N.Y. and ...

The FDA has approved Sanofi and Regeneron’s Dupixent as a treatment for adults with bullous pemphigoid, a rare chronic autoimmune skin condition that causes severe itching, painful blisters and open ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are ...

TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...